PharmAthene tumbles after BARDA cuts SparVax funds
This article was originally published in Scrip
Executive Summary
Shares of biodefense firm PharmAthene tumbled almost 10% on 7 April after the company revealed the Biomedical Advanced Research and Development Authority (BARDA) decided not to fund new research and development activities involving the company's experimental recombinant protective (rPA) anthrax vaccine SparVax.